Antibody-Drug Conjugates (ADCs): A Novel Therapy for Triple-Negative Breast Cancer (TNBC)

doi:10.2174/0115680096343056240828190900

. 2025;25(2):108-112.

doi: 10.2174/0115680096343056240828190900.

Antibody-Drug Conjugates (ADCs): A Novel Therapy for Triple-Negative Breast Cancer (TNBC)

Gaurav Gupta^{1

2}, Md Sadique Hussain³, Kumud Pant^{4

5}, Haider Ali^{6

7}, Riya Thapa³, Asif Ahmad Bhat³

Affiliations

¹ Chitkara College of Pharmacy, Chitkara University, Rajpura, Chandigarh, India.
² Centre of Medical and Bio-allied Health Sciences Research, Ajman University, Ajman, United Arab Emirates.
³ Uttaranchal Institute of Pharmaceutical Sciences, Uttaranchal University, Dehradun, Uttarakhand 248007, India.
⁴ Graphic Era (Deemed to be University) Clement Town Dehradun- 248002, India.
⁵ Graphic Era Hill University, School of Pharmaceutical Sciences, Clement Town Dehradun- 248002, India.
⁶ Centre for Global Health Research, Saveetha Medical College, Saveetha Institute of Medical and Technical Sciences, Saveetha University, India.
⁷ Department of Pharmacology, Kyrgyz State Medical College, Bishkek, Kyrgyzstan.

PMID: 39248064
DOI: 10.2174/0115680096343056240828190900

Antibody-Drug Conjugates (ADCs): A Novel Therapy for Triple-Negative Breast Cancer (TNBC)

Gaurav Gupta et al. Curr Cancer Drug Targets. 2025.

. 2025;25(2):108-112.

doi: 10.2174/0115680096343056240828190900.

Authors

Gaurav Gupta^{1

2}, Md Sadique Hussain³, Kumud Pant^{4

5}, Haider Ali^{6

7}, Riya Thapa³, Asif Ahmad Bhat³

Affiliations

¹ Chitkara College of Pharmacy, Chitkara University, Rajpura, Chandigarh, India.
² Centre of Medical and Bio-allied Health Sciences Research, Ajman University, Ajman, United Arab Emirates.
³ Uttaranchal Institute of Pharmaceutical Sciences, Uttaranchal University, Dehradun, Uttarakhand 248007, India.
⁴ Graphic Era (Deemed to be University) Clement Town Dehradun- 248002, India.
⁵ Graphic Era Hill University, School of Pharmaceutical Sciences, Clement Town Dehradun- 248002, India.
⁶ Centre for Global Health Research, Saveetha Medical College, Saveetha Institute of Medical and Technical Sciences, Saveetha University, India.
⁷ Department of Pharmacology, Kyrgyz State Medical College, Bishkek, Kyrgyzstan.

PMID: 39248064
DOI: 10.2174/0115680096343056240828190900

No abstract available

Keywords: Antibody-drug conjugates; Sacituzumab govitecan; Trop2 antigen; clinical trial.; triple-negative breast cancer.

PubMed Disclaimer

Cited by

Tailored therapies for triple-negative breast cancer: current landscape and future perceptions.
Khan Y, Rizvi S, Raza A, Khan A, Hussain S, Khan NU, Alshammari SO, Alshammari QA, Alshammari A, Ellakwa DE. Khan Y, et al. Naunyn Schmiedebergs Arch Pharmacol. 2025 Aug;398(8):9425-9450. doi: 10.1007/s00210-025-03896-4. Epub 2025 Mar 3. Naunyn Schmiedebergs Arch Pharmacol. 2025. PMID: 40029385 Review.
Patterns of immune evasion in triple-negative breast cancer and new potential therapeutic targets: a review.
Serrano García L, Jávega B, Llombart Cussac A, Gión M, Pérez-García JM, Cortés J, Fernández-Murga ML. Serrano García L, et al. Front Immunol. 2024 Dec 13;15:1513421. doi: 10.3389/fimmu.2024.1513421. eCollection 2024. Front Immunol. 2024. PMID: 39735530 Free PMC article. Review.
Exosomes derived from natural killer cells: transforming immunotherapy for aggressive breast cancer.
Alfawaz Altamimi AS, Arockia Babu M, Afzal M, Bishoyi AK, Roopashree R, Saini S, Sharma RSK, Pathak PK, Chauhan AS, Goyal K, Ali H, Khan NH, Balaraman AK. Alfawaz Altamimi AS, et al. Med Oncol. 2025 Mar 18;42(4):114. doi: 10.1007/s12032-025-02647-y. Med Oncol. 2025. PMID: 40100465 Review.
Metabolomics as a tool for understanding and treating triple-negative breast cancer.
Khan G, Hussain MS, Ahmad S, Alam N, Ali MS, Alam P. Khan G, et al. Naunyn Schmiedebergs Arch Pharmacol. 2025 May 2. doi: 10.1007/s00210-025-04234-4. Online ahead of print. Naunyn Schmiedebergs Arch Pharmacol. 2025. PMID: 40314763 Review.

References

1. Abdus Subhan M.; Torchilin V.P.; Advances with antibody-drug conjugates in breast cancer treatment. Eur J Pharm Biopharm 2021,169,241-255 - DOI - PubMed
1. Ritchie M.; Tchistiakova L.; Scott N.; Implications of receptor-mediated endocytosis and intracellular trafficking dynamics in the development of antibody drug conjugates. MAbs 2013,5(1),13-21 - DOI - PubMed
1. Mahalingaiah P.K.; Ciurlionis R.; Durbin K.R.; Yeager R.L.; Philip B.K.; Bawa B.; Mantena S.R.; Enright B.P.; Liguori M.J.; Van Vleet T.R.; Potential mechanisms of target-independent uptake and toxicity of antibody-drug conjugates. Pharmacol Ther 2019,200,110-125 - DOI - PubMed
1. Giugliano F.; Corti C.; Tarantino P.; Michelini F.; Curigliano G.; Bystander effect of antibody–drug conjugates: Fact or fiction? Curr Oncol Rep 2022,24(7),809-817 - DOI - PubMed
1. Maqbool M.; Bekele F.; Fekadu G.; Treatment strategies against triple-negative breast cancer: An updated review. Breast Cancer (Dove Med Press) 2022,14,15-24 - DOI - PubMed

LinkOut - more resources

Full Text Sources
- Bentham Science Publishers Ltd.
Research Materials
- NCI CPTC Antibody Characterization Program
Miscellaneous
- NCI CPTAC Assay Portal

[1] Abdus Subhan M.; Torchilin V.P.; Advances with antibody-drug conjugates in breast cancer treatment. Eur J Pharm Biopharm 2021,169,241-255 - DOI - PubMed

[2] Abdus Subhan M.; Torchilin V.P.; Advances with antibody-drug conjugates in breast cancer treatment. Eur J Pharm Biopharm 2021,169,241-255 - DOI - PubMed

[3] Ritchie M.; Tchistiakova L.; Scott N.; Implications of receptor-mediated endocytosis and intracellular trafficking dynamics in the development of antibody drug conjugates. MAbs 2013,5(1),13-21 - DOI - PubMed

[4] Ritchie M.; Tchistiakova L.; Scott N.; Implications of receptor-mediated endocytosis and intracellular trafficking dynamics in the development of antibody drug conjugates. MAbs 2013,5(1),13-21 - DOI - PubMed

[5] Mahalingaiah P.K.; Ciurlionis R.; Durbin K.R.; Yeager R.L.; Philip B.K.; Bawa B.; Mantena S.R.; Enright B.P.; Liguori M.J.; Van Vleet T.R.; Potential mechanisms of target-independent uptake and toxicity of antibody-drug conjugates. Pharmacol Ther 2019,200,110-125 - DOI - PubMed

[6] Mahalingaiah P.K.; Ciurlionis R.; Durbin K.R.; Yeager R.L.; Philip B.K.; Bawa B.; Mantena S.R.; Enright B.P.; Liguori M.J.; Van Vleet T.R.; Potential mechanisms of target-independent uptake and toxicity of antibody-drug conjugates. Pharmacol Ther 2019,200,110-125 - DOI - PubMed

[7] Giugliano F.; Corti C.; Tarantino P.; Michelini F.; Curigliano G.; Bystander effect of antibody–drug conjugates: Fact or fiction? Curr Oncol Rep 2022,24(7),809-817 - DOI - PubMed

[8] Giugliano F.; Corti C.; Tarantino P.; Michelini F.; Curigliano G.; Bystander effect of antibody–drug conjugates: Fact or fiction? Curr Oncol Rep 2022,24(7),809-817 - DOI - PubMed

[9] Maqbool M.; Bekele F.; Fekadu G.; Treatment strategies against triple-negative breast cancer: An updated review. Breast Cancer (Dove Med Press) 2022,14,15-24 - DOI - PubMed

[10] Maqbool M.; Bekele F.; Fekadu G.; Treatment strategies against triple-negative breast cancer: An updated review. Breast Cancer (Dove Med Press) 2022,14,15-24 - DOI - PubMed

Save citation to file

Email citation

Add to Collections

Add to My Bibliography

Your saved search

Create a file for external citation management software

Your RSS Feed

Antibody-Drug Conjugates (ADCs): A Novel Therapy for Triple-Negative Breast Cancer (TNBC)

Affiliations

Antibody-Drug Conjugates (ADCs): A Novel Therapy for Triple-Negative Breast Cancer (TNBC)

Authors

Affiliations

Similar articles

Cited by

References

LinkOut - more resources

Full Text Sources

Research Materials

Miscellaneous

Similar articles

Cited by

References

Related information

LinkOut - more resources

Full Text Sources

Research Materials

Miscellaneous